Increased Movement Of People Making Dengue Outbreaks More Common, Says Mosquito Expert
Greg Devine said mosquitos that carry the virus 'hitchhike around the world' and the increased movement of people is increasing those infected by dengue. Caleb Fotheringham, RNZ Pacific Journalist
Dengue fever outbreaks have been surging in recent decades but new initiatives like infecting mosquitos with bacteria or genetic modification could dramatically slow the spread.
According to the World Health Organization there was just over 500,0000 reported cases in 2000 – ballooning to 5.2 million in 2019.
Last year, there were 14 million dengue cases – a record number dwarfing the previous 2023 high of 6.5 million.
This year, there's been 2.5 million.
Samoa, Fiji, Tonga and the Cook Islands have all declared dengue outbreaks. Samoa, Fiji and Tonga have each had at least one death from the viral infection.
Greg Devine from the World Mosquito Program said increased globalisation is making outbreaks more common.
Devine said mosquitos that carry the virus 'hitchhike around the world' and the increased movement of people is increasing those infected by dengue.
Devine said a lot of people also don't have immunity.
'They don't have any protection against it because they've never been exposed to it before,' he said.
'Dengue comes in four different serotypes, so just because you've had one doesn't mean you can't get another.'
He said climate change was having an increasing impact.
'We are hotter and wetter than we've ever been before and that's great for mosquitoes. It also means that the virus in mosquitoes is replicating more rapidly.'
The aedes aegypti mosquito – which carries dengue – is considered a tropical or subtropical mosquito, but Devine said warmer weather would also increase the mosquitoes' range of where it inhabits.
In the Pacific, health ministries are trying to stamp out mosquito breeding grounds and are spraying insecticides outside.
But Devine said doing so has had limited success in reducing the spread.
He said the aedes aegypti mosquito is 'completely reliant upon humans for its blood meals' which meant it liked to stay indoors, not outdoors where the majority of the spraying happens.
'Outdoor use of insecticides, it's perhaps better than nothing and the truth is that the community wants to see something happening.
'That's a very visible intervention but the reality is, there's a very limited evidence base for its impact.'
Mosquitoes continually exposed to insecticides would also evolve resistance, Devine said.
The World Mosquito Programme infects mosquitos with a naturally occurring bacteria called Wolbachia, which stops viruses like dengue growing in the mosquitoes' bodies.
'It's been trialled in New Caledonia, where it's been extremely successful,' Devine said.
'In the years since, the mosquito releases have been made by the World Mosquito Program, there's been no dengue epidemics where once they were extremely common.'
He said genetically modified mosquitoes were also being looked at as a solution.
'That's a different kind of strategy, where you release large numbers of mosquitoes which have been modified in a way which means when those males interact with the local mosquito female population, the resulting offspring are not viable, and so that can crash the entire population.'
When asked if that could collapse the entire aedes aegypti mosquito population, Devine said he wouldn't be 'particularly worried about decimating numbers'.
'People often refer to it as the kind of cockroach of the mosquito world.
'It's very, very closely adapted to the human population in most parts of its range. The species evolved in Africa and has since, spread throughout the world. It's not a particularly important mosquito for many ecosystems.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
1News
10 hours ago
- 1News
It's not just 'chronic fatigue': ME/CFS is much more than being tired
Myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is as complex as its name is difficult to pronounce. It's sometimes referred to as simply "chronic fatigue", but this is just one of its symptoms. In fact, ME/CFS is a complex neurological disease, recognised by the World Health Organization, that affects nearly every system in the body. The name refers to muscle pain (myalgia), inflammation of the brain (encephalomyelitis), and a profound, disabling fatigue that rest can't relieve. However, the illness's complexity – and its disproportionate impact on women – means ME/CFS has often been incorrectly labelled as a psychological disorder. What is ME/CFS? ADVERTISEMENT ME/CFS affects people of all ages but is most commonly diagnosed in middle age. It is two to three times more common in women than men. While the exact cause is unknown, ME/CFS is commonly triggered by an infection. The condition has two core symptoms: a disabling, long-lasting fatigue that rest doesn't relieve, and a worsening of symptoms after physical or mental exertion. This is known as post-exertional malaise. It means even slight exertion can make symptoms much worse, and take much longer than expected to recover. This varies between people, but could mean simply having a shower or attending a social event triggers worse symptoms, either immediately or days later. These symptoms include pain, sleep issues, cognitive difficulties (such as thinking, memory and decision-making), flu-like symptoms, dizziness, gastrointestinal problems, heart rate fluctuations and many more. For some people, symptoms can be managed in a way that allows them to work. For others, the disease is so severe it can leave them housebound or bedridden. ADVERTISEMENT Symptoms can fluctuate, changing over time and in intensity, making ME/CFS a particularly unpredictable and misunderstood condition. Not just 'in your head' A person at home (file image). (Source: A growing body of scientific evidence, however, clearly shows ME/CFS is a biological, not mental, illness. Neuroimaging studies have revealed differences in the brain activity and structure of people with ME/CFS, including poor blood flow and lower levels of neurotransmitters (chemical messengers in the nervous system). Other research indicates the condition affects how the body produces energy (the metabolism), fights infection (the immune system), delivers oxygen to muscles and tissues, and regulates blood pressure and heart rate (the vascular system). Issues with criteria ADVERTISEMENT To diagnose ME/CFS, a clinician will also exclude other possible causes of fatigue, which can be a lengthy process. A patient needs to meet a set of clinical criteria. But one of the major challenges in researching ME/CFS is that the diagnostic criteria clinicians use vary worldwide. Some criteria focus solely on fatigue and include people with alternate reasons for fatigue, such as a psychiatric disorder. Others are more narrow and may only capture ME/CFS patients with more severe symptoms. As a result, it can be very difficult to compare across different studies, as the reasons they include or exclude participants vary so much. Changes to the guidelines In Australia, doctors often receive little formal education about ME/CFS. ADVERTISEMENT Most commonly, they follow the Royal Australian College of General Practitioners' clinical guidelines to diagnose and manage ME/CFS. These are based on the Canadian Consensus Criteria which are considered more stringent than other ME/CFS diagnostic criteria. They include post-exertional malaise and fatigue for more than six months as core symptoms. However, these guidelines are outdated and rely heavily on controversial studies that assumed the primary cause of ME/CFS was 'deconditioning' – a loss of physical strength due to a fear or avoidance of exercise. These guidelines recommend ME/CFS should be treated with cognitive behavioural therapy – a common psychotherapy which focuses on changing unhealthy thoughts and behaviours – and graded exercise therapy, which gradually introduces more demanding physical activity. While cognitive behaviour therapy can be effective for some people managing ME/CFS, it's important not to frame this condition primarily as a psychological issue. Graded exercise therapy can encourage people to push beyond their 'energy envelope', which means they do more than their body can manage. This can trigger post-exertional malaise and a worsening of symptoms. In June 2024, the Australian government announced A$1.1 million (NZ$1.2 million) towards developing new clinical guidelines for diagnosing and managing ME/CFS. ADVERTISEMENT Leading organisations have scrapped the recommendation of graded exercise therapy in the United States (in 2015) and the United Kingdom (in 2021). Hopefully Australia will follow suit. What can people with ME/CFS do? While we wait for updated clinical guidelines, 'pacing' – or working within your energy envelope – has shown some success in managing symptoms. This means monitoring and limiting how much energy you expend. Some evidence also suggests people who rest in the early stages of their initial illness often experience better long-term outcomes with ME/CFS. This is especially relevant after the Covid-19 pandemic and with the emergence of long Covid. Studies indicate more than half of those affected meet stringent clinical criteria for ME/CFS. In times of acute illness we should resist the temptation to push through. Choosing to rest may be a crucial step in preventing a condition that is much more debilitating than the original infection. Author: Sarah Annesley is a senior postdoctoral research fellow in cell and molecular biology at La Trobe University in Melbourne, Australia This article is republished from The Conversation under a Creative Commons licence.
Scoop
4 days ago
- Scoop
Make Midwives Universally Accessible And Save Millions Of Lives, WHO Urges
18 June 2025 According to the World Health Organization (WHO), this sort of large-scale life-saving is possible, if midwifery care is universally accessible and consistent with international standards. ' Expanding and investing in midwifery models of care is one of the most effective strategies to improve maternal and newborn health globally,' said Dr. Anshu Banerjee, director for maternal, child and adolescent health and ageing at WHO. In a recently released report, WHO outlined how individual countries, with the support of the international community, can mobilise relevant stakeholders and institute policies which support midwives. Midwifery models of care Midwives worldwide work diligently to provide a continuum of care to women, including care surrounding sexual and reproductive health, pregnancy, childbirth and postnatal care. Emphasizing personalized and culturally conscious approaches, midwifery is especially helpful in reducing access barriers for women in rural or conflict-affected regions where hospitals may not be accessible. 'Skilled midwives help women trust in their bodies, their abilities and their care…ensuring women are consistently part of decision making and have access to the information they need,' said Ulrika Rehnstrom Loi, a midwifery expert at WHO. The WHO report emphasised that midwifery models of care are especially important as concerns of over-medicalisation in childbirth become more pronounced. 'In a world where childbirth is increasingly medicalised, [midwives] offer a person-centered evidence-based approach that respects the physiological process of birth, restores dignity and autonomy to maternity care,' said Anna Ugglas, Chief Executive of the International Confederation of Midwives. Implementing a global imperative Currently, the world faces a global shortage of around one million midwives. Concentrated and cross-sectoral action is needed to reverse this shortage. 'Midwifery models of care are not just smart solutions — they are a necessity,' Ms. Ugglas said. The WHO report outlined that increasing the number of midwives worldwide requires policy action across many sectors, including health and education, in addition to advocacy campaigns. In Morocco, the Association of Midwives conducted an awareness campaign which distributed flyers and cultivated partnerships with women and civil society organizations. This campaign ultimately led to legislation in 2016 which defined what midwifery was, the first of its kind in Morocco. Like the Moroccan example indicates, the report said that policymaking, advocacy and implementation must all happen simultaneously and that each country must adopt an approach which is specific to their context. '[Midwifery] approaches improve outcomes, maximize resources and can be adapted to all countries,' said Dr. Banerjee. Case study in rural midwifery A campaign in the West Bank led by the Palestinian Red Crescent Society, the Palestine Committee of Norway and the Palestinian Ministry of Health worked to address the challenges that women in rural areas face when accessing care. Through coordinating with hospitals and community members, the campaign expanded midwifery services to six regional hospitals and 37 villages between 2013 and 2016. This led to a 20 per cent decrease in unplanned caesarean sections and a 21 per cent decline in preterm birth rates. And these were just the short-term effects, but Mr. Banerjee said that expanded midwifery access can have longer-term effects too. '[Midwifery models of care] also enhance women's and families' experiences of care – building trusted partnerships for health at this critical stage of life.'
Scoop
7 days ago
- Scoop
Include Males Too In Addressing Human Papilloma Virus And Related Cancers
Press Release – CNS Human Papilloma Virus (HPV) is a common sexually transmitted infection. Since an effective HPV vaccine exists and HPV screening and treatment of pre-cancer lesions can save lives, no one should be suffering from any of the HPV related cancer or … Human Papilloma Virus (HPV) is a common sexually transmitted infection. Since an effective HPV vaccine exists and HPV screening and treatment of pre-cancer lesions can save lives, no one should be suffering from any of the HPV related cancer or had to die of it. According to the World Health Organization (WHO), HPV do not cause health concerns in most infected people (of all genders), but persistent HPV infection with some high-risk genotypes is common and can cause genital warts or cancer. For example, almost all cervical cancer, which is the 4th top cancers among women worldwide, is caused by HPV. HPV also causes cancers of vulva, vagina, mouth/throat (oropharyngeal), penis and anus. Despite cervical cancer being preventable and curable (if detected early and managed effectively), more than 660,000 women developed cervical cancer in 2022. Over 350,000 women died of cervical cancer in 2022. In 2019, HPV caused over 70,000 cancer cases in men too. HPV screening must be done with DNA test, not pap smear or VIA 'We have a large burden of cervical cancer in India – one woman dies every 8 minutes due to this preventable cancer. All women above the age of 30 years, must undergo cervical cancer screening with an HPV DNA molecular test (and not by pap smear or visual inspection with acetic acid – VIA),' said Dr Smita Joshi, a noted scientist who has made a significant contribution to advancing HPV vaccine and screening research and science-backed interventions in the past two decades. National Family Health Survey (NFHS) of India 2019-2021 shows that among women age 15-49, only 1.2% ever got a screening for cervical cancer in India. WHO Cervical Cancer Elimination Initiative (adopted in 2021) sets the goal of at least 70% of the eligible women to get screened. 'There is a large gap in HPV screening of eligible women in India,' points out Dr Joshi. Dr Joshi leads the Department of Preventive Oncology, Prayas (a non-profit). Dr Joshi has been a principal investigator for HPV vaccine and cervical cancer related research studies of WHO's IARC (International Agency for Research on Cancer) since 2009. She also serves as Programme Director at Jahangir Clinical Development Centre (JCDC) in Pune, India. Connect the dots: HPV, HIV and all genders Women living with HIV are at 6 times higher risk of HPV-related cervical cancer compared to those without HIV. HPV also infects men. For example, studies show that rates of HPV have shown to be alarmingly high among men who have sex with men. Mumbai-based microbiologist and researcher Dr Prapti Gilada-Toshinwal presented an important study at 10th Asia Pacific AIDS and Co-Infections Conference (APACC 2025) in Japan. This study was done to determine the prevalence of HPV anal infection among 105 men who have sex with men who were seeking care at Unison Medicare and Research Centre (a comprehensive infectious diseases centre) between August 2022 and December 2024. It is important to note that Unison Medicare and Research Centre has been serving around 10,000 people living with HIV since last 35 years. Around 80% study participants came from Mumbai and rest of them were from other cities of India except 3 who came from other countries. '70% of study participants were living with HIV,' said Dr Prapti Gilada. 'Overall, anal HPV infection rate was 62%.' She serves as CEO and consultant microbiologist at UniLabs Diagnostics. 'Some of them also had other sexually transmitted infections such as syphilis, chlamydia, or gonorrhoea.' 'In the study we offered DNA test for HPV to all eligible study participants (105 men who have sex with men) who were receiving medical care at our centre. Most common HPV high risk genotype was 16. Other common high-risk HPV genotypes found among study participants were 18 and 45,' said Dr Prapti Gilada. 'HPV positivity rates were higher in those study participants who were also living with HIV (68.5%) compared to those without HIV (48%),' said Dr Prapti Gilada, who is also an independent Director of Thyrocare. Global data shows that among men who have sex with men, HPV is higher among those who are living with HIV than those without it. She was speaking with CNS before 2nd Asia Pacific Conference on Point-of-Care Diagnostics for Infectious Diseases (POC 2025) and 13th International AIDS Society Conference on HIV Science (IAS 2025) open. Dr Prapti Gilada calls for raising awareness, health and treatment literacy among the masses so that eligible boys and men and girls and women can access HPV vaccination, HPV screening and management of pre-cancerous lesions and other health issues. She also hopes governments will make HPV vaccination available to all those eligible of all genders, as well as screening and appropriate management. Dr Prapti Gilada cites a study published in The Lancet in 2023 which showed that almost 1 in 3 men over the age of 15 were infected with at least one genital HPV genotype, and 1 in 5 men were infected with one or more of high risk (or oncogenic) HPV genotypes. It is high time all eligible boys and men too are included in HPV responses globally Agrees Vijay Nair who is the Chairperson of Udaan Trust and a prominent community rights activist from India: 'With no HPV vaccination and screening facilities for males, there are people who have even probably died with undiagnosed HPV-related anal cancers or other health issues. Some may be getting services for piles or anal fissures or fistula as there is hardly any HPV screening facilities for anal HPV. We need to screen high-risk men for HPV and HPV related health conditions including pre-cancerous lesions or anal cancers. Also, we need to include males too for vaccination against HPV.' Vijay was speaking at the India's National Dialogue and Stakeholder Consultation held last month in preventing cancers and addressing ageing among people living with HIV. It was organised by National Coalition of People Living with HIV in India (NCPI Plus). Colposcopy and anoscopy: Do we have enough facilities? Those with persistent HPV infection may need a specialised follow up medical examination with colposcopy (medical experts examine with an equipment for any HPV-related changes or abnormalities in vulva, vagina or cervix of women) or anoscopy (medical experts examine with an equipment for any HPV-related changes or abnormalities in anus or rectum). If any changes or abnormalities, further appropriate medical treatment is required. 'We need more medical centres for anoscopy,' said Dr Prapti Gilada whose study participants may require further follow up. Her centre is continuing to follow up with all the study participants, one of whom has become HPV negative during the study. Dr Smita Joshi is a widely recognised colposcopy trainer too. 'We have screened over 40,000 women for HPV and cervical cancer and managed them appropriately as per the WHO latest guidelines.' Her centre at Prayas is a recognised colposcopy centre too which has trained several medical professionals including gynaecologists from within India and other countries too. She appeals for financial resources to scale up trainings of medical professionals in India and other countries which would go a long way in strengthening capacities and competencies towards addressing HPV and related cancers. Addressing HPV lacks ambition Governments have promised to eliminate cervical cancer by end of this century. In order to be on track towards cervical cancer elimination, all countries must reach and maintain an incidence rate of below 4 per 100,000 women. Achieving that goal rests on 3 key pillars and their corresponding targets to be achieved by 2030 so that countries are on track towards eliminating cervical cancer by end of the century. – vaccination: 90% of all eligible young people must be fully vaccinated with the HPV vaccine by the age of 15 – screening: 70% of women should be screened using a high-performance test by the age of 35, and again by the age of 45 – treatment: 90% of women with pre-cancer treated and 90% of women with invasive cancer managed. Cervical cancer is preventable as vaccines exist since almost two decades now. HPV screening and DNA tests exist. Medical management of pre-cancerous lesions can save lives and avert cancers. Is not a goal to eliminate cervical cancer by turn of this century, lacking ambition? India's first indigenously validated Truenat HPV-HR Plus test in April 2025 Indian government announced in April 2025, India's first indigenously developed and point-of-care HPV DNA molecular test is Truenat HPV-HR Plus test that screens people for 8 high-risk genotypes (16, 18, 31, 33, 35, 45, 52 and 58). These 8 high-risk HPV genotypes cause over 96% of cervical cancers globally. Truenat HPV-HR Plus is developed by Indian company (Molbio Diagnostics). Its independent multi-centric validation was done by Government of India's Department of Biotechnology, Biotechnology Industry Research Assistance Council (BIRAC) and Grand Challenges India. This independent validation of Truenat HPV-HR Plus was conducted under the study 'Validating Indigenous Human Papilloma Virus (HPV) Tests for Cervical Cancer Screening in India.' The study involved leading Indian government's research institutes, including All India Institute of Medical Sciences (AIIMS) Delhi, ICMR National Institute for Cancer Prevention and Research (NICPR) Noida, and ICMR National Institute for Research in Reproductive and Child Health (NIRRCH) Mumbai, in collaboration with WHO's International Agency for Research on Cancer (IARC). However, Truenat HPV-HR DNA molecular test has been around for over 2 years now to screen people for 4 high-risk genotypes. Follow the science: Vaccinate and screen all eligible people for HPV and related cancers Dr Smita Joshi led several researchers in her distinguished career over two decades. She was part of a multi-centric study of WHO's IARC on HPV vaccine which was initiated in 2009 onwards. This study was to evaluate efficacy of HPV vaccine (2 doses vs 3 doses at 0, 2 and 6 months). However, due to government's order to stop HPV vaccination in studies (owing to adverse outcomes in a PATH study), Dr Joshi's study also had to stop vaccination abruptly in April 2009. 'Because of that suspension of HPV vaccinatio, instead of two versus three doses, this study resulted in a cohort of girls that had received only a single dose, two doses (at 0 and 2 months), two doses (at 0 and 6 months) and three doses (at 0, 2 and 6 months). So, the long-term follow-up of these vaccinated girls is still being carried out since then,' said Dr Joshi. 'We have now completed 15 years of the study and of immunogenicity data.' Dr Joshi's study majorly impacted and contributed to informing vaccine dosage in many countries as well as to WHO's recommendation of single dose HP vaccination in the young girls. She was also part of the HPV vaccine study (for India's indigenously developed HPV vaccine Ceravac). She wonders when HPV vaccine would become a part of Indian government's public vaccination programme. Some Indian states (like Sikkim, Delhi, Punjab) had introduced HPV vaccination using a foreign-made vaccine) but latest information on status of these programmes is not with us. Dr Prapti Gilada and Udaan's Vijay Nair too call for including HPV vaccination for those eligible from all genders in the government's programme at the earliest – as well as HPV screening and management of all related health conditions especially pre-cancerous lesions and cancers. Dr Smita Joshi adds that when government of India includes indigenously developed HPV vaccine in its programme, then 'one good thing about Ceravac of Serum Institute of India is that it is also approved for boys. Appeal to world leaders who will meet at UNHLM on NCDs Next High Level Meeting on Non-Communicable Diseases (UNHLM on NCDs) will happen in September 2025 at the United Nations General Assembly. Although HPV is an infection, yet it causes one of the top cancers worldwide. We appeal to world leaders to commit to scale up HPV vaccination for all those eligible (regardless of genders), and screen all eligible people (regardless of gender) for HPV and related pre-cancerous and cancerous conditions. Developing vaccine or point-of-care diagnostics is not enough but deploying them at point-of-need in the Global South is critical pathway towards increasing access to lifesaving services and improving HPV-related responses on the ground. Shobha Shukla – CNS (Citizen News Service) (Shobha Shukla is the award-winning founding Managing Editor and Executive Director of CNS (Citizen News Service) and is a feminist, health and development justice advocate. She is a former senior Physics faculty of prestigious Loreto Convent College and current Coordinator of Asia Pacific Regional Media Alliance for Health and Development (APCAT Media) and Chairperson of Global AMR Media Alliance (GAMA received AMR One Health Emerging Leaders and Outstanding Talents Award 2024). She also coordinates SHE & Rights initiative (Sexual health with equity & rights). Follow her on Twitter @shobha1shukla or read her writings here
